Zynerba Pharmaceuticals

Dedicated to the development of innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders

Learn More

Our mission is to improve the lives of patients battling severe rare and near-rare neuropsychiatric disorders including Fragile X syndrome and certain refractory epilepsies including developmental and epileptic encephalopathies (DEE).

Our Team

Our Team

Our team has a proven track record of success in developing novel transdermal products for patients in need.

More >>

Our Development Pipeline

Our Development Pipeline

We are developing a proprietary pharmaceutically-produced transdermally-delivered CBD gel in multiple neuropsychiatric indications, including Fragile X syndrome and certain refractory epilepsies.

More >>

For Investors

For Investors

Learn more about our company and our potential.

More >>

Latest News

1120

Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

Learn More

1108

Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

Learn More